7-methyl-5-(2-methyl-4-pyridinyl)-1-(oxan-2-yl)-6-propan-2-ylpyrazolo[4,3-g]isoquinolin-7-ium
C25H29N4O+ — CID 156879629
Data last refreshed: (MolForge compound catalog, from PubChem)
About 7-methyl-5-(2-methyl-4-pyridinyl)-1-(oxan-2-yl)-6-propan-2-ylpyrazolo[4,3-g]isoquinolin-7-ium
7-methyl-5-(2-methyl-4-pyridinyl)-1-(oxan-2-yl)-6-propan-2-ylpyrazolo[4,3-g]isoquinolin-7-ium (PubChem CID 156879629) has the molecular formula C25H29N4O+ and a molecular weight of 401.53 g/mol. Its IUPAC name is 7-methyl-5-(2-methyl-4-pyridinyl)-1-(oxan-2-yl)-6-propan-2-ylpyrazolo[4,3-g]isoquinolin-7-ium.
Molecular Properties
| Compound Name | 7-methyl-5-(2-methyl-4-pyridinyl)-1-(oxan-2-yl)-6-propan-2-ylpyrazolo[4,3-g]isoquinolin-7-ium |
|---|---|
| PubChem CID | 156879629 |
| Molecular Formula | C25H29N4O+ |
| Molecular Weight | 401.53 g/mol |
| Exact Mass | 401.23 |
| IUPAC Name | 7-methyl-5-(2-methyl-4-pyridinyl)-1-(oxan-2-yl)-6-propan-2-ylpyrazolo[4,3-g]isoquinolin-7-ium |
| SMILES | Cc1cc(-c2c(C(C)C)[n+](C)cc3cc4c(cnn4C4CCCCO4)cc23)ccn1 |
| InChI | InChI=1S/C25H29N4O/c1-16(2)25-24(18-8-9-26-17(3)11-18)21-12-19-14-27-29(23-7-5-6-10-30-23)22(19)13-20(21)15-28(25)4/h8-9,11-16,23H,5-7,10H2,1-4H3/q+1 |
| InChIKey | NJMXTXWXEXQMOZ-UHFFFAOYSA-N |
| XLogP | 5.21 |
| TPSA | 43.82 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 30 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 401.53 |
| LogP ≤ 5 | 5.21 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 4 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'quaternary_nitrogen_1', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 156879629 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.